Boro Dropulic
Principal investigator.
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2006First federal award
$6.5MFederal grants as PI10 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
10 awards · $6.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 1, 2009 | NIH | SBIR/STTR Phase I A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus | $283K | — |
| Sep 15, 2008 | NIH | SBIR/STTR Phase I Lentiviral expressed growth factors as a novel therapy in wound healing | $119K | — |
| Aug 31, 2007 | NIH | SBIR/STTR Phase I T cell receptor gene vectors for EBV disease | $134K | — |
| Apr 15, 2007 | NIH | SBIR/STTR Phase I Lentiviral Vectors for TCR Immunotherapy Targeted to HCV | $290K | — |
| Sep 28, 2006 | NIH | SBIR/STTR Phase I Lentiviral Vectors for TCR Immunotherapy Targeted to melanoma | $243K | — |
| Sep 28, 2006 | NIH | SBIR/STTR Phase II Clinical Vector for TCR Immunotherapy Targeted to Melanoma | $1.7M | — |
| Sep 28, 2006 | NIH | SBIR/STTR Phase II Clinical Vector for TCR Immunotherapy Targeted to Melanoma | $2.2M | — |
| Sep 28, 2006 | NIH | SBIR/STTR Phase II Clinical Vector for TCR Immunotherapy Targeted to Melanoma | $1.2M | — |
| Sep 12, 2006 | NIH | SBIR/STTR Phase I Immunotherapy of CLL with lentiviral expressed CD40-ligand | $115K | — |
| Sep 1, 2006 | NIH | SBIR/STTR Phase I Lentiviral engineered T cell immunotherapy in tumors overexpressing mesothelin | $237K | — |
1 patents as inventor
- US —
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#42
Awards as PI#55
Patents#27
Companies
No tracked company linked yet.
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.